XML 52 R39.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

IN-LICENSING AND ACQUISITION - Narrative (Details) - USD ($) $ in Thousands |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Feb. 22, 2024 | Jul. 31, 2024 | Jul. 27, 2022 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2022 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2022 | Dec. 31, 2023
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  | $ 5,540 | $ 4,772 |  | $ 11,566 | $ 14,861 |  |
Intangible asset |  |  |  | 28,275 |  |  | $ 28,275 |  |  | $ 13,878
Forma |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront fee |  |  | $ 2,000 |  |  |  |  |  |  |
Research and development |  |  |  |  |  |  |  |  | $ 2,000 |
Forma | Commercial milestones |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Potential payments |  |  | 165,500 |  |  |  |  |  |  |
Forma | Development and regulatory milestones |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Potential payments |  |  | $ 67,500 |  |  |  |  |  |  |
Forma | Achievement of certain near-term regulatory milestone |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Research and development |  |  |  |  |  | $ 2,500 |  |  |  |
GAVRETO (pralsetinib) |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Intangible assets, estimated useful life |  |  |  |  |  |  | 12 years |  |  |
REZLIDHIA |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Intangible assets, estimated useful life |  |  |  |  |  |  | 14 years |  |  |
REZLIDHIA | Forma | FDA approval and first commercial sale of product |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Intangible asset |  |  |  |  |  | $ 15,000 |  |  | $ 15,000 |
Blueprint |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Asset purchase agreement, drug product inventories |  |  |  | $ 6,500 |  |  | $ 6,500 |  |  |
Blueprint | GAVRETO (pralsetinib) |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Asset acquisition, expected price | $ 15,000 |  |  |  |  |  |  |  |  |
Blueprint | GAVRETO (pralsetinib) | Subsequent event |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Acquisition payment |  | $ 10,000 |  |  |  |  |  |  |  |
Blueprint | GAVRETO (pralsetinib) | Minimum |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Potential tiered royalties (as a percentage) | 10.00% |  |  |  |  |  |  |  |  |
Blueprint | GAVRETO (pralsetinib) | Maximum |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Potential tiered royalties (as a percentage) | 30.00% |  |  |  |  |  |  |  |  |
Blueprint | GAVRETO (pralsetinib) | First commercial sale |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Asset acquisition, expected price | $ 10,000 |  |  |  |  |  |  |  |  |
Blueprint | GAVRETO (pralsetinib) | First anniversary of the closing date |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Asset acquisition, expected price | 5,000 |  |  |  |  |  |  |  |  |
Blueprint | GAVRETO (pralsetinib) | Commercial milestones |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Potential milestone payments | 97,500 |  |  |  |  |  |  |  |  |
Blueprint | GAVRETO (pralsetinib) | Regulatory milestones |  |  |  |  |  |  |  |  |  |
Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Potential milestone payments | $ 5,000 |  |  |  |  |  |  |  |  |

X
- Definition Amount of agreement for purchase of drug product inventories. + References No definition available. + Details
Name: | rigl_AssetPurchaseAgreementDrugProductInventories
Namespace Prefix: | rigl_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Maximum amount of contingent payments under collaborative arrangement. + References No definition available. + Details
Name: | rigl_CollaborativeArrangementPotentialPayments
Namespace Prefix: | rigl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of collaborative arrangement upfront payment. + References No definition available. + Details
Name: | rigl_CollaborativeArrangementUpfrontPayment
Namespace Prefix: | rigl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of potential milestone payment obligations. + References No definition available. + Details
Name: | rigl_PotentialMilestonePaymentObligations
Namespace Prefix: | rigl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The percentage of potential tiered royalties. + References No definition available. + Details
Name: | rigl_PotentialTieredRoyaltyPercentage
Namespace Prefix: | rigl_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Purchase price of expected asset acquisition prior to consideration being transferred. Excludes business acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3 + Details
Name: | us-gaap_AssetAcquisitionPriceOfAcquisitionExpected
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance. + References No definition available. + Details
Name: | us-gaap_IntangibleAssetsNetIncludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_SpecifiedCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_AchievementOfCertainNearTermRegulatoryMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rigl_GavretoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rigl_RezlidhiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_FdaApprovalAndFirstCommercialSaleOfProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=rigl_BlueprintMedicinesCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_FirstCommercialSaleMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_FirstAnniversaryOfClosingDateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_RegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |